- Designed to replace glucocerebrosidase (the enzyme that is deficient or missing in people with Gaucher disease)
- A prescription medicine for use in people with type 1 Gaucher disease
- Derived from a human cell line
- Designed to have an amino acid sequence identical to naturally occurring human protein
Your doctor can determine if VPRIV is right for you. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.
Find out more information about starting treatment with VPRIV.
For more information about Gaucher disease, including other types of the condition, go to gaucherpatients.com.